| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/30/2006 | WO2006033630A1 Compounds, compositions containing them, preparation thereof and uses thereof iii |
| 03/30/2006 | WO2006033453A1 Activity enhancer for interferon agent |
| 03/30/2006 | WO2006033007A2 Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| 03/30/2006 | WO2006033006A2 Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
| 03/30/2006 | WO2006032921A1 Bioreductively-activated prodrugs |
| 03/30/2006 | WO2006032908A1 Bioreductively-activated prodrugs |
| 03/30/2006 | WO2006032869A1 Dna-pk inhibitors |
| 03/30/2006 | WO2006032704A2 Diagnostic compounds for targeting a chemokine receptor |
| 03/30/2006 | WO2006032631A1 Inhibitors of the interaction between mdm2 and p53 |
| 03/30/2006 | WO2006032537A2 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 03/30/2006 | WO2006032525A2 Combinational therapy for treating cancer |
| 03/30/2006 | WO2006032520A1 Oxazole derivatives as her tyrosine kinase inhibitors |
| 03/30/2006 | WO2006032519A1 Tricycles, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | WO2006032509A1 Indole derivatives, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | WO2006032453A1 1,2,3 -triazole derivatives as receptor tyrosine kinase inhitors |
| 03/30/2006 | WO2006032086A1 Chroman derivatives, medicaments and use in therapy |
| 03/30/2006 | WO2006032085A1 Substituted chroman derivatives, medicaments and use in therapy |
| 03/30/2006 | WO2005123736A8 Novel 2-benzylaminodihydropteridinones, method for producing them and use thereof as drugs |
| 03/30/2006 | WO2005120643A3 Use of 7-t-butoxyiminomethylcamptothecin for treating uterine neoplasms |
| 03/30/2006 | WO2005118643A3 Antibodies to angiogenesis inhibiting domains of cd148 |
| 03/30/2006 | WO2005117867A3 Monocyclic heterocycles as kinase inhibitors |
| 03/30/2006 | WO2005090372A3 Platinum carboxylate anticancer compounds |
| 03/30/2006 | WO2005030124A3 Antibodies to m-csf |
| 03/30/2006 | WO2005014077A3 Catheter balloon systems and methods |
| 03/30/2006 | WO2004070012A3 Cell-killing molecules and methods of use thereof |
| 03/30/2006 | WO2003014294A3 Tacis and br3 polypeptides and uses thereof |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069154 Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs |
| 03/30/2006 | US20060069140 Pyrazolone compounds and thrombopoietin receptor activator |
| 03/30/2006 | US20060069131 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
| 03/30/2006 | US20060069130 Novel crystals |
| 03/30/2006 | US20060069129 Chemokine receptor binding heterocyclic compounds |
| 03/30/2006 | US20060069126 Pharmaceutically active isoindoline derivatives |
| 03/30/2006 | US20060069109 Therapeutic agents |
| 03/30/2006 | US20060069105 Protein tyrosine kinase inhibitors |
| 03/30/2006 | US20060069103 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 03/30/2006 | US20060069092 Pharmaceutical compositions for the treatment of diseases related to neurotrophines |
| 03/30/2006 | US20060069084 Methods of inhibiting kinases |
| 03/30/2006 | US20060069077 Receptor-type kinase modulators and methods of use |
| 03/30/2006 | US20060069067 Combination of an aromatase inhibitor with a bisphosphonate |
| 03/30/2006 | US20060069057 Medicaments containing xenogeneic oligo- and/or polyribonucleotides |
| 03/30/2006 | US20060069028 A carbamate or urea containing comopound is useful to treat angiogeneisis; methionine aminopeptidase 2 (MetAP-2) coupled to a peptide prevents the metabolic degradation of the angiogenesis inhibitor compound |
| 03/30/2006 | US20060069025 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068453 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068035 Method of preparation and composition of a water soluble extract of the bioactive component of the plant species Uncaria for enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals |
| 03/30/2006 | US20060068027 Methods for regulating levels of zinc, cadmium and calcium in humans and for diagnosing, or screening for the risk of developing, diseases associated with abnormal levels of cadmium, zinc and calcium in body fluids and tissues |
| 03/30/2006 | US20060067947 Immunotherapeutic for cancer |
| 03/30/2006 | US20060067946 Method of treatment using ligand-immunogen conjugates |
| 03/30/2006 | US20060067934 DNA sequences encoding tumor necrosis factor receptors; recombinant expression vectors |
| 03/30/2006 | US20060067932 Antagonists specific for denatured collagen and methods of using same |
| 03/30/2006 | US20060067928 Contacting a linear polysaccharide with a disaccharide repeat unit of a uronic acid [ alpha -L-iduronic acid (I) or beta -D-glucuronic acid] linked 1, 4 to alpha -D-hexosamine with a modified heparinase III in vitro |
| 03/30/2006 | US20060067919 Colon cancer metastasis inhibitor |
| 03/30/2006 | US20060067914 Immortalized natural killer cell line |
| 03/30/2006 | US20060067910 Polyethylene glycol-polyglutamic acid block copolymer conjugates with e.g. 7-ethyl-10-hydroxycamptothecin or topotecan for sustained release; water solubility, anticancer agents |
| 03/30/2006 | US20060067885 ablating a targeted non-malignant B cell, comprising administering to a human subject having an immune disease an unconjugated monoclonal antibody (LL2 antibody) which binds to a marker that is specific for a B cell |
| 03/30/2006 | US20060067884 for radiolabeling proteins, peptides and ligands with therapeutic radioisotopes such that these radiolabeled agents may be administered directly to patients without the need for additional purification; for the treatment of cancer |
| 03/30/2006 | DE19911771B4 LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung LHRH antagonist, process for its preparation and its use |
| 03/30/2006 | CA2588280A1 Oxazole derivatives as her tyrosine kinase inhibitors |
| 03/30/2006 | CA2582766A1 Isomigrastatin analogs in the treatment of cancer |
| 03/30/2006 | CA2582507A1 Compounds, compositions containing them, preparation thereof and uses thereof iii |
| 03/30/2006 | CA2581450A1 Bioreductively-activated prodrugs |
| 03/30/2006 | CA2581316A1 Substituted chroman derivatives, medicaments and use in therapy |
| 03/30/2006 | CA2581200A1 Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
| 03/30/2006 | CA2581150A1 (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors |
| 03/30/2006 | CA2581101A1 Inorganic selenium for treatment of cancer |
| 03/30/2006 | CA2580881A1 Use of microproteins as tryptase inhibitors |
| 03/30/2006 | CA2580749A1 Quinolone analogs |
| 03/30/2006 | CA2580725A1 Novel heterocyclic nf-kb inhibitors |
| 03/30/2006 | CA2580229A1 Dna-pk inhibitors |
| 03/30/2006 | CA2580215A1 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 03/30/2006 | CA2580203A1 Tricycles, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | CA2580198A1 Novel phthalazinone derivatives as aurora-a kinase inhibitors |
| 03/30/2006 | CA2579905A1 Cytotoxicity mediation of cells evidencing surface expression of mcsp |
| 03/30/2006 | CA2579412A1 Indole derivatives, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | CA2579408A1 1,2,3 -triazole derivatives as receptor tyrosine kinase inhibitors |
| 03/30/2006 | CA2579406A1 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors |
| 03/30/2006 | CA2579169A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| 03/30/2006 | CA2578824A1 Crystalline form 2 of atrasentan hydrochloride |
| 03/29/2006 | EP1640898A1 Medical care self-cell delivery support system, medical care self-cell delivery support financial system, and their methods |
| 03/29/2006 | EP1640458A1 Method of selecting patients suitable for wt1 vaccine |
| 03/29/2006 | EP1640452A1 OLIGO DOUBLE-STRANDED RNA INHIBITING THE EXPRESSION OF Bcl-2 AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| 03/29/2006 | EP1640380A1 Histone deacetylase inhibitor and process for producing the same |
| 03/29/2006 | EP1640371A1 Flavanone compound and uses thereof |
| 03/29/2006 | EP1640018A1 Combinational therapy for treating cancer |
| 03/29/2006 | EP1640010A1 Agent inducing increase in bone mass |
| 03/29/2006 | EP1640004A1 Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| 03/29/2006 | EP1640002A1 Indazole derivatives for inhibition of angiogenesis |
| 03/29/2006 | EP1639108A2 Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides |
| 03/29/2006 | EP1639010A2 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease |
| 03/29/2006 | EP1638987A2 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same |
| 03/29/2006 | EP1638978A2 7-substituted camptothecin and camptothecin analogs and methods for preparing same |
| 03/29/2006 | EP1638964A1 Novel compounds that modulate ppar-gamma type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 03/29/2006 | EP1638954A1 Fused azoles such as 2,5-disubstituted benzimidazoles, benzoxazoles and benzothiazoles as kinase inhibitors |
| 03/29/2006 | EP1638943A2 Novel imidazole derivatives, the production thereof, and the use of the same as a medicament |
| 03/29/2006 | EP1638941A1 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| 03/29/2006 | EP1638613A1 Combination therapy of oxaliplatin and radioactively doped particles treating cancer |
| 03/29/2006 | EP1638591A1 Class iii slrp agonists for the reduction of blood vessel formation |
| 03/29/2006 | EP1638580A2 Use of double-stranded ribonucleic acid for inducing cell lysis |
| 03/29/2006 | EP1638572A1 Use of roscovitine for treating lymphocytic leukemia |
| 03/29/2006 | EP1638571A1 Combination comprising a cdk inhibitor and a topoisomerase i inhibitor for the treatment of cancer and other proliferative diseases |